Cancer Research
Correction
Correction: miR145 Targets the SOX9/ ADAM17 Axis to Inhibit Tumor-Initiating Cells and IL6-Mediated Paracrine Effects in Head and Neck Cancer In this article (Cancer Res 2013;73:3425–40), which appeared in the June 1, 2013, issue of Cancer Research (1), there are errors in Fig. 3. In panels A and B, the Sox9 and GAPDH loading control blots in ALDH1þCD44þ HNC cells and ALDH1CD44 HNC cells were inadvertently duplicated. The authors provided corrected results; the corrected panels appear below. These errors do not change either the results or the conclusions of the article. The authors regret these errors.
Figure 3.
Reference 1. Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 2013;73:3425–40. Published OnlineFirst June 16, 2015. doi: 10.1158/0008-5472.CAN-15-1351 Ó2015 American Association for Cancer Research.
www.aacrjournals.org
Downloaded from cancerres.aacrjournals.org on July 10, 2015. © 2015 American Association for Cancer Research.
2761
Correction: miR145 Targets the SOX9/ADAM17 Axis to Inhibit Tumor-Initiating Cells and IL6-Mediated Paracrine Effects in Head and Neck Cancer Cancer Res 2015;75:2761.
Updated version
Cited articles
E-mail alerts Reprints and Subscriptions Permissions
Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/75/13/2761
This article cites 1 articles, 1 of which you can access for free at: http://cancerres.aacrjournals.org/content/75/13/2761.full.html#ref-list-1
Sign up to receive free email-alerts related to this article or journal. To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [email protected]. To request permission to re-use all or part of this article, contact the AACR Publications Department at [email protected].
Downloaded from cancerres.aacrjournals.org on July 10, 2015. © 2015 American Association for Cancer Research.
Correction
Correction: miR145 Targets the SOX9/ ADAM17 Axis to Inhibit Tumor-Initiating Cells and IL6-Mediated Paracrine Effects in Head and Neck Cancer In this article (Cancer Res 2013;73:3425–40), which appeared in the June 1, 2013, issue of Cancer Research (1), there are errors in Fig. 3. In panels A and B, the Sox9 and GAPDH loading control blots in ALDH1þCD44þ HNC cells and ALDH1CD44 HNC cells were inadvertently duplicated. The authors provided corrected results; the corrected panels appear below. These errors do not change either the results or the conclusions of the article. The authors regret these errors.
Figure 3.
Reference 1. Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 2013;73:3425–40. Published OnlineFirst June 16, 2015. doi: 10.1158/0008-5472.CAN-15-1351 Ó2015 American Association for Cancer Research.
www.aacrjournals.org
Downloaded from cancerres.aacrjournals.org on July 10, 2015. © 2015 American Association for Cancer Research.
2761
Correction: miR145 Targets the SOX9/ADAM17 Axis to Inhibit Tumor-Initiating Cells and IL6-Mediated Paracrine Effects in Head and Neck Cancer Cancer Res 2015;75:2761.
Updated version
Cited articles
E-mail alerts Reprints and Subscriptions Permissions
Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/75/13/2761
This article cites 1 articles, 1 of which you can access for free at: http://cancerres.aacrjournals.org/content/75/13/2761.full.html#ref-list-1
Sign up to receive free email-alerts related to this article or journal. To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [email protected]. To request permission to re-use all or part of this article, contact the AACR Publications Department at [email protected].
Downloaded from cancerres.aacrjournals.org on July 10, 2015. © 2015 American Association for Cancer Research.
